PMID- 21381013
OWN - NLM
STAT- MEDLINE
DCOM- 20110512
LR  - 20191210
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 117
IP  - 6
DP  - 2011 Mar 15
TI  - Peripheral blood monitoring of chronic myeloid leukemia during treatment with 
      imatinib, second-line agents, and beyond.
PG  - 1245-52
LID - 10.1002/cncr.25678 [doi]
AB  - BACKGROUND: The current study was conducted to compare simultaneously obtained 
      bone marrow (BM) cytogenetics (CTG), peripheral blood (PB) and BM fluorescence in 
      situ hybridization (FISH), and quantitative real-time polymerase chain reaction 
      (Q-PCR) for BCR-ABL1 in monitoring response to treatment with tyrosine kinase 
      inhibitors and homoharringtonine (HHT) in patients with chronic myeloid leukemia 
      (CML). METHODS: PB and BM FISH (n = 112 samples) and/or Q-PCR (n = 132 samples) 
      for BCR-ABL1 were simultaneously obtained in 70 patients with Philadelphia 
      chromosome-positive (Ph+) CML in chronic (68%), accelerated (16%), and blast 
      phase (16%) before the initiation of therapy and during the course of treatment 
      with imatinib (IM) (n = 40 patients), dasatinib (n = 20 patients), nilotinib (n = 
      4 patients), bosutinib (n = 18 patients), or HHT (n = 4 patients) for patients 
      with newly diagnosed (n = 13 patients), IM-sensitive (n = 34 patients), 
      IM-resistant (n = 30 patients), or IM-intolerant (n = 9 patients) disease. 
      Eighteen patients were found to have Ph+ variants or karyotypic abnormalities in 
      addition to the Ph+. RESULTS: Excellent correlations (r) were observed between PB 
      and BM FISH (r = 0.95) and PB and BM Q-PCR (r = 0.87), as well as BM CTG and PB 
      FISH (r = 0.89) and PB Q-PCR (r = 0.82). This correlation was not affected by the 
      presence of the Ph+ variant or additional chromosomal abnormalities, the presence 
      of ABL1 kinase domain mutations, phase of the disease, or treatment. CONCLUSIONS: 
      PB FISH and Q-PCR appear to be reliable methods with which to monitor response to 
      modern therapy in patients with all phases of CML.
CI  - Copyright (c) 2010 American Cancer Society.
FAU - Lima, Lisa
AU  - Lima L
AD  - Department of Hematology and Medial Oncology, Emory University School of Medicine 
      and Winship Cancer Institute of Emory University, Atlanta, Georgia 30322, USA.
FAU - Bernal-Mizrachi, Leon
AU  - Bernal-Mizrachi L
FAU - Saxe, Debra
AU  - Saxe D
FAU - Mann, Karen P
AU  - Mann KP
FAU - Tighiouart, Mourad
AU  - Tighiouart M
FAU - Arellano, Martha
AU  - Arellano M
FAU - Heffner, Leonard
AU  - Heffner L
FAU - McLemore, Morgan
AU  - McLemore M
FAU - Langston, Amelia
AU  - Langston A
FAU - Winton, Elliott
AU  - Winton E
FAU - Khoury, Hanna Jean
AU  - Khoury HJ
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20101102
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzamides)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 8A1O1M485B (Imatinib Mesylate)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*administration & dosage/therapeutic use
MH  - Benzamides
MH  - Chemotherapy, Adjuvant
MH  - Cytogenetic Analysis/economics/methods
MH  - Drug Administration Schedule
MH  - Female
MH  - Hematologic Tests/methods
MH  - Humans
MH  - Imatinib Mesylate
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*blood/diagnosis/*drug 
      therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Monitoring, Physiologic/economics/methods
MH  - Neoplasm Staging/economics/methods
MH  - Piperazines/*therapeutic use
MH  - Polymerase Chain Reaction/methods
MH  - Prognosis
MH  - Pyrimidines/*therapeutic use
MH  - Retrospective Studies
MH  - Young Adult
EDAT- 2011/03/08 06:00
MHDA- 2011/05/13 06:00
CRDT- 2011/03/08 06:00
PHST- 2010/05/07 00:00 [received]
PHST- 2010/06/28 00:00 [revised]
PHST- 2010/08/25 00:00 [accepted]
PHST- 2011/03/08 06:00 [entrez]
PHST- 2011/03/08 06:00 [pubmed]
PHST- 2011/05/13 06:00 [medline]
AID - 10.1002/cncr.25678 [doi]
PST - ppublish
SO  - Cancer. 2011 Mar 15;117(6):1245-52. doi: 10.1002/cncr.25678. Epub 2010 Nov 2.